Tammy Evans-Strickfaden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tammy Evans-Strickfaden has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Angela Holder
Laboratory Branch, Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
1 shared publication - Beatrice Nyagol
KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya
1 shared publication - Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
1 shared publication - Boaz Oyaro
HIV Research Branch, Kenya Medical Research Institute, Kisumu, Kenya
1 shared publication - Eleanor McLellan-Lemal
Centers for Disease Control and Prevention, Office of Infectious Diseases, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of HIV/AIDS Prevention, Atlanta, GA, USA
1 shared publication - Esther M Makang
KEMRI/CDC Research Field Station, P.O. Box 1578, Kisumu, Kenya
1 shared publication
Latest Publications
- 1 June 2017
- Published by Elsevier in Contraception
- Vol. 95 (6) , 602-604
Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use
- 1 June 2017
- Published by Elsevier in Contraception
- Vol. 95 (6) , 602-604
Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use
- Open Access
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Open AccessNovel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.